Live from ASH 2024 First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with RR Ph ALL
| IIMOX Fund | USD 6.04 0.01 0.17% |
Slightly above 56% of Voya Midcap's investor base is looking to short. The analysis of overall sentiment of trading Voya Midcap Opportunities mutual fund suggests that many investors are alarmed at this time. Voya Midcap's investing sentiment can be driven by a variety of factors including economic data, Voya Midcap's earnings reports, geopolitical events, and overall market trends.
Voya |
Ascentage Pharma , a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released the safety and efficacy data of the companys novel drug candidate, olverembatinib , in combination the companys investigational novel Bcl-2 inhibitor, lisaftoclax , in children and adolescents with relapsedrefractory Philadelphia chromosomeposit
Read at finance.yahoo.com
 |
Voya Midcap Fundamental Analysis
We analyze Voya Midcap's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Voya Midcap using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Voya Midcap based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Year To Date Return
Year To Date Return Comparative Analysis
Voya Midcap is currently under evaluation in year to date return among similar funds. Year to Date Return (YTD) is the total return generated from holding a security from the beginning of the current fiscal year. In other words, YTD Return represents the capital appreciation of your investments from the start of the current fiscal year.
Voya Midcap Opportunities Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Voya Midcap mutual fund to make a market-neutral strategy. Peer analysis of Voya Midcap could also be used in its relative valuation, which is a method of valuing Voya Midcap by comparing valuation metrics with similar companies.
Peers
Voya Midcap Related Equities
| IMCVX | Voya Multi | 1.07 | ||||
| ILABX | Voya Bond | 0.22 | ||||
| ILBPX | Voya Limited | 0.11 | ||||
| IMBAX | Voya Limited | 0.11 | ||||
| IMCDX | Voya Emerging | 0.00 | ||||
| ILMBX | Voya Limited | 0.10 | ||||
| IMORX | Voya Midcap | 0.17 | ||||
| IMOPX | Voya Midcap | 0.26 | ||||
| ILBAX | Voya Bond | 0.33 | ||||
| ILUAX | Voya Bond | 0.34 |
Other Information on Investing in Voya Mutual Fund
Voya Midcap financial ratios help investors to determine whether Voya Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Voya with respect to the benefits of owning Voya Midcap security.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |